Disease Landscape and Forecast Insights

The treatment of multiple myeloma has advanced considerably in recent years with Celgene’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remaining  key cornerstones of treatment…

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy despite the availability of several treatment options. Resistance to therapy is the primary treatment challenge…

The multiple myeloma therapy market has witnessed considerable advances in recent years. Effective therapies such as Thalomid, Revlimid, Velcade, Pomalyst, and Kyprolis have transformed the…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who the…

Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant…

Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…

Market Outlook Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…

Multiple label expansions of premium-priced agents and the launch of four novel therapies will fuel the significant growth of the multiple myeloma market over the ten-year forecast period. The…

In China, multiple myeloma treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and thalidomide—while the treatment for…

This three-wave syndicated research series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for…